Valuing Pharmaceutical Innovation: Pricing and reimbursement for innovative therapies

Published by: Business Insights

Published: Jul. 1, 2008 - 121 Pages

Table of Contents

Valuing pharmaceutical innovation

Executive Summary

Introduction

Categorizing and valuing innovation

Region and therapy area specific considerations

Pricing challenges for recently launched innovative therapies

Upcoming launches of new innovative therapies

Chapter 1 Introduction

Summary

Introduction

Supply-side factors

Complexity and costs

Market size

Competition

Demand-side factors

Budget

Unmet need

Competition

Valuing innovation

Chapter 2 Categorizing and valuing innovation

Summary

Introduction

Categories of innovations

New market innovations

Redefining the category innovations

Second generation innovations

Incremental therapeutic innovations

Incremental formulation innovations

Innovative market access strategies

Orphan drugs

Risk-sharing

Chapter 3 Region and therapy area specific considerations

Summary

Introduction

Approaches to market access in major markets

USA

Japan

France

Germany

Italy

Spain

UK

Therapy area markets for innovative therapies

Oncology

HIV

Autoimmune diseases

Diabetes

Others

Chapter 4 Pricing challenges of recently launched innovative therapies

Summary

Introduction

New market innovations

Gardasil (human papilloma virus vaccine): changing the treatment algorithm

Lysosomal storage diseases: pricing versus patient weight

Redefining the category innovations

Chantix (varenicline): redefining a therapeutic category

Nexavar (sorafenib) versus Sutent (sunitinib): meeting an unmet need

Second generation innovations

Lyrica (pregabalin): a new, improved neuropathic pain drug

Macugen vs Lucentis vs Avastin : premium pricing against off-label use

Incremental therapeutic innovations

Byetta vs Januvia: changing the treatment paradigm for type 2 diabetes

Prezista vs Fuzeon: premium pricing in HIV/AIDS

Incremental formulation innovations

Abraxane (paclitaxel): pricing incremental convenience

Vivitrol: market access vs premium pricing

Chapter 5 Upcoming launches of new innovative therapies

Summary

Introduction

New market innovations

Lupuzor (IPP-201101) - ImmuPharma

Sinunase - Accentia

Redefining the category innovations

Bapineuzumab - Elan/Wyeth

Multikine - CelSci

Second generation innovations

Arzoxifene - Eli Lilly

Cordaptive (niacin ER/laropiprant) - Merck

Incremental therapeutic innovations

Naproxcinod - NicOx

RhuDex - MediGene

Incremental formulation innovations

Denosumab - Amgen

Xarelto (rivaroxaban) - Bayer/J&J

Chapter 6 Appendix

Research sources

Pricing data

List of Figures

Figure 1.1: Supply and demand factors impacting market access for innovative therapies

Figure 2.2: Innovative drug categories by level of innovation and ease of market access

Figure 3.3: Source of prescription drug expenditures in the US, 2005-2006

Figure 3.4: Italian categorization for innovative new therapies

Figure 4.5: Gardasil global sales, 2006-07 ($m)

Figure 4.6: Selected lysosomal storage disease drugs global sales, 2006-07

Figure 4.7: Selected lysosomal storage disease drugs pricing in the UK and US, 2008

Figure 4.8: Smoking cessation drugs global sales, 2006-07

Figure 4.9: Smoking cessation drugs pricing in the UK and US, 2008

Figure 4.10: Nexavar and Sutent global sales, 2006-07

Figure 4.11: Nexavar and Sutent pricing in the UK and US, 2008

Figure 4.12: Selected neuropathic pain drugs global sales, 2006-07

Figure 4.13: Selected neuropathic pain drugs pricing in the UK and US, 2008

Figure 4.14: Age-related macular degeneration drugs global sales, 2006-07

Figure 4.15: Age-related macular degeneration drugs pricing in the UK and US, 2008

Figure 4.16: Selected type 2 diabetes drugs global sales, 2006-07

Figure 4.17: Selected type 2 diabetes drugs pricing in the UK and US, 2008

Figure 4.18: Selected HIV/AIDS drugs global sales, 2006-07

Figure 4.19: Selected HIV/AIDS drugs pricing in the UK and US, 2008

Figure 4.20: Taxane drugs global sales, 2006-07

Figure 4.21: Taxane drugs pricing in the US, 2008

Figure 4.22: Alcohol dependency drugs global sales, 2006-07

Figure 4.23: Alcohol dependency drugs pricing in the US, 2008

List of Tables

Table 3.1: Classification for price premium (Japanese healthcare system)

Table 4.2: Gardasil pricing in the UK and US, 2008

Table 4.3: Selected lysosomal storage disease drugs pricing in the UK and US, 2008

Table 4.4: Smoking cessation drugs pricing in the UK and US, 2008

Table 4.5: Nexavar and Sutent pricing in the UK and US, 2008

Table 4.6: Selected neuropathic pain drugs pricing in the UK and US, 2008

Table 4.7: Age-related macular degeneration drugs pricing in the UK and US, 2008

Table 4.8: Selected type 2 diabetes drugs pricing in the UK and US, 2008

Table 4.9: Selected HIV/AIDS drugs pricing in the UK and US, 2008

Table 4.10: Taxane drugs pricing in the UK and US, 2008

Table 4.11: Alcohol dependency drugs pricing in the UK and US, 2008

Table 5.12: Selected innovative therapies currently in late stage development

Table 6.13: Key UK and US pricing data for leading case studies, 2008

Table 6.13: Key UK and US pricing data for leading case studies, 2008 (continued)

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.